Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C.

Introduction: Although it is standard procedure in the evaluation of liver diseases, biopsy is an invasive method subject to sampling error and intra or inter-observer variability. Thus, surrogate markers of liver fibrosis have been proposed, with variable availability and accuracy.

Aim: Validate and compare the performance of APRI and FIB-4 as predictors of liver fibrosis in HCV patients.